SCHEMBL2856173

SCHEMBL2856173

COc1ccc(Cn2c(=O)c3c(N)n(-c4ccc(Oc5ccccc5)c(OC)c4)nc3c3ccc(OC(C)C)cc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
THRB P10828 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NTRK1 P04629 2/20 0.38
NTRK2 Q16620 2/20 0.38
NTRK3 Q16288 1/20 0.38
TP53 P04637 2/20 0.37
BTK Q06187 1/20 0.37
PLA2G10 O15496 1/20 0.37
S1PR3 Q99500 2/20 0.36
IGF1R P08069 1/20 0.36
FGFR1 P11362 1/20 0.36
MCHR1 Q99705 1/20 0.35
PLA2G2A P14555 2/20 0.35
HPGD P15428 2/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2867619 0.92 BCL2 (0.40) MEN1GAAMAPTMAPK1KMT2A
SCHEMBL2860751 0.90 P2RX4 (0.44) MEN1GAAMAPTKMT2ATHRB
SCHEMBL2858941 0.88 GAA (0.38) MEN1GAAMAPTMAPK1KMT2A
SCHEMBL2862341 0.88 PDE1B (0.40) GAAMAPTMAPK1TP53PLA2G10
SCHEMBL2861196 0.88 MAPK1 (0.42) MEN1GAAMAPTMAPK1KMT2A
SCHEMBL2862981 0.84 PLA2G10 (0.39) MEN1GAAMAPK1KMT2ASMN1; SMN2
SCHEMBL2865409 0.84 KDM4E (0.41) MAPTKMT2ASMN1; SMN2TP53ALDH1A1
SCHEMBL2867245 0.83 NPBWR1 (0.40) MAPTTP53NPBWR1
SCHEMBL2865416 0.81 S1PR3 (0.41) MEN1GAAMAPTMAPK1KMT2A
SCHEMBL2857641 0.81 PDE1B (0.38) MEN1GAAMAPTMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 MEN1 3903/4885GAA 4868/4885MAPT 4583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.